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Inhibition of cytochrome P450 (CYP)-mediated retinoic acid (RA) metabolism by RA 
metabolism blocking agents (RAMBAs) increases endogenous retinoids and is an alternative to 
retinoid therapy. Currently available RAMBAs (i.e. liarozole and talarozole) tend to have fewer 
adverse effects than traditional retinoids but lack target specificity. Substrate-based inhibitor 
DX314 has enhanced selectivity for RA-metabolizing enzyme CYP26B1 and may offer an 
improved treatment option for keratinization disorders such as congenital ichthyosis and Darier 
disease. In this study we use RT-qPCR, RNA sequencing, pathway, upstream regulator, and 
histological analyses to demonstrate that DX314 can potentiate the effects of all-trans-RA 
(atRA) in healthy and diseased reconstructed human epidermis (RHE). We unexpectedly 
discovered that DX314, but not atRA or previous RAMBAs, appears to protect epidermal barrier 
integrity. Additionally, DX314-induced keratinization and epidermal proliferation effects are 
observed in a rhino mice model. Altogether, results indicate that DX314 inhibits atRA 
metabolism with minimal off-target activity and shows therapeutic similarity to topical retinoids 
in vitro and in vivo. Findings of a unique barrier-protecting effect require further mechanistic 
study but may lead to a novel strategy in barrier-reinforcing therapies. DX314 is a unique and 
promising candidate compound for further study and development in the context of 
keratinization disorders.
































































Therapeutics targeting retinoid biopathways have been implemented in the clinical 
treatment of keratinization disorders such as the congenital ichthyoses (Vahlquist et al. 2008), 
Darier disease (DD) (Casals et al. 2009; Cooper and Burge 2003; Dicken et al. 1982; Steijlen et 
al. 1993), and other skin disorders (e.g. acne, psoriasis) (Dawson and Dellavalle 2013; Fisher and 
Voorhees 1996) to alleviate patient symptoms. Such therapies leverage the role of endogenous 
retinoids in regulating keratinocyte proliferation and differentiation. Retinoid bioactivity is 
primarily, although not solely, mediated by transcription factors such as retinoic acid receptors 
(RAR) and retinoid X receptors (RXR) (Fisher et al. 1994).
However, retinoid treatments also result in adverse effects including dry skin, irritation, 
redness, photosensitivity, teratogenicity and barrier impairment (Orfanos et al. 1997). 
Endogenously-occurring retinoids (e.g. tretinoin) autoinduce their own metabolism (Van Der 
Leede et al. 1997; Marikar et al. 1998), which in turn demands higher exogenous doses for 
effective treatment, resulting in increased systemic exposure. Synthetic retinoids, particularly 
tazarotenic acid, will both activate RARs and inhibit RA-metabolism (Foti et al. 2016), which 
may overstimulate retinoid biopathways and increase associated adverse effects. For these 
reasons, RA metabolism blocking agents (RAMBAs) (Verfaille et al. 2008), including liarozole 
and talarozole, were developed to target the primary RA-specific metabolizing enzymes of the 
cytochrome p450 family 26 (CYP26) (Ray et al. 1997).
RAMBAs, particularly when used topically, achieve therapeutic effects without high 
exposure to systemic levels of RA by utilizing endogenously available RA rather than high doses 
of exogenous retinoids, which theoretically reduces overexposure and adverse effects. Topical 
RAMBAs could be implemented either as standalone treatments or as adjunct therapies to reduce 































































oral retinoid dosing without loss of therapeutic efficacy. Reports illustrate successful inhibition 
of RA metabolism using liarozole (Van Wauwe et al. 1992) and proven efficacy in treating 
several skin disorders (Berth-Jones et al. 2000; Bhushan et al. 2001; Kang et al. 1996; Kuijpers 
et al. 1998; Lucker et al. 2005; Lucker et al. 1997; Vahlquist et al. 2014), including in a 
comparative trial vs acitretin (an oral retinoid) for congenital ichthyosis, which showed a trend 
towards a better safety profile (Verfaille et al. 2007b). Problematically, liarozole also inhibits 
off-target CYPs such as aromatase (CYP19), an important enzyme in estradiol biosynthesis 
(Nelson et al. 2013). Previous RAMBAs have not progressed past clinical trials, suggesting the 
need for improved RAMBA candidates.
The promising results of early-generation RAMBAs led Diaz et al. to develop a series of 
compounds targeting RA metabolism via specific inhibition of two CYP26 isoforms (A1 and B1) 
(Diaz et al. 2016). Removal of the heme-interacting azole moiety, thought to contribute to the 
non-specific effects of previous azole-containing RAMBAs, may preserve the desired effects 
while minimizing off-target activity. One of these compounds, a CYP26B1-specific inhibitor, 
DX314 (IC50: CYP26A1=1752nM; CYP26B1=108nM), was described in US patent 
US009963439B2 as example 39 (Diaz et al. 2018).
Endogenous all-trans-RA (atRA) is a well-known regulator of epidermal proliferation 
and differentiation (Fisher and Voorhees 1996), in part by inducing heparin-binding EGF-like 
growth factor (HBEGF), which stimulates keratinocyte proliferation (Rittié et al. 2006; Stoll and 
Elder 1998; Xiao et al. 1999; Yoshimura et al. 2003), and involucrin (IVL), a late marker of 
epidermal differentiation (Eckert et al. 2004; Monzon et al. 1996; Poumay et al. 1999). 
Expression of both CYP26A1 and CYP26B1 is induced by atRA, but only the CYP26A1 































































promotor contains a RA response element (RARE) which directly binds RARs (Pavez Loriè et 
al. 2009a). 
In this study, we investigate RAMBAs in vitro under tightly-controlled growth conditions 
that specifically do not contain RA or RA precursors (Giltaire et al. 2009; Minner et al. 2010; 
Pavez Loriè et al. 2009a; Poumay et al. 1999). In these conditions, a highly specific RAMBA 
will have a negligible effect in the absence of atRA, however when co-treated with a nanomolar 
dose of atRA, facilitate a relative increase in atRA concentration by inhibiting its metabolism, 
and therefore potentiate the expression of RA-responsive genes. Since in vivo concentrations of 
atRA in healthy human skin are typically 2-4nM (Mihály et al. 2011), we co-treated RAMBAs in 
vitro with 1nM atRA to provide a near-physiological basal level, without saturating nanomolar-
sensitive atRA effects, which allowed us to observe if RAMBAs can potentiate those effects. 
Skin acts as an effective barrier to the environment. Changes in epidermal barrier 
integrity can be investigated using transepithelial electrical resistance (TEER) and 
transepidermal water loss (TEWL). TEER is an in vitro assay assessing electrical properties to 
evaluate possible changes in trans- and paracellular (regulated by tight junctions) ion 
permeability across the epidermis. TEWL measures passive diffusion of water across the 
epidermis and can be performed in vivo or in vitro. Decreased TEER or increased TEWL 
typically indicates barrier integrity disruption.
Our data show that DX314 potentiates the effects of atRA on gene expression in healthy 
and diseased epidermis by inhibiting CYP26B1-mediated RA metabolism. Unexpectedly, 
DX314 mitigated the epidermal barrier dysregulation and irregular morphology displayed by 
other RAMBAs and high dose atRA. In addition, topical DX314 induced comedolytic/anti-































































keratinizing effects in the rhino mouse model, reflecting those observed in previous retinoid 
studies (Ashton et al. 1984; Fort-Lacoste et al. 1999; Kligman and Kligman 1979). 
Together, this study suggests that DX314 exhibits potential as a new keratinization 
disorder therapeutic that may address some shortcomings of previous retinoid-based treatments.
RESULTS
DX314 potentiates the effects of atRA in healthy and keratinization disorder keratinocytes
Based on RT-qPCR assays, a 4-day atRA treatment of RHE caused a dose-dependent 
increase in HBEGF, CYP26A1 and IVL gene expression (Figure 1a). DX314, together with 
near-physiological dosing of atRA (1nM; to provide basal RA without saturating sensitive RA 
pathways) mimics the consequences of high dose atRA on the expression of every gene 
analyzed, indicating potentiation of atRA. Liarozole with atRA significantly increases HBEGF 
and CYP26A1 expression relative to control, but only CYP26A1 expression is potentiated 
compared to 1nM atRA alone.
Immunostaining shows IVL (Figure 1b) primarily localized in the upper epidermis of 
control and DX314-alone RHE. Induction of early IVL expression is observed in basal and 
suprabasal layers of the epidermis with atRA-alone, and even more so, DX314 with 1nM atRA. 
RNAseq confirmed that DX314 alone (atRA-free conditions) had no effect on HBEGF, 
IVL, CYP26A1 or CYP26B1 mRNA expression (Figure 1c), and that DX314 potentiated the 
effects of 1nM atRA, not only on these genes, but on numerous other known retinoid-responsive 
genes, among them several keratins (KRT) (Radoja et al. 1997), lecithin:retinol acyl-transferase 
(LRAT) (Kurlandsky et al. 1996), retinol binding protein 1 (RBP1) (Kang et al. 1995), and 
cellular retinoic acid binding protein 2 (CRABP2) (Aström et al. 1994). Changes in expression of 































































other genes that involve both direct (RARE-containing promotor, indicated by adjacent green 
box) (Aström et al. 1992; Fisher et al. 1995; Lalevée et al. 2011; Laursen et al. 2015; Loudig et 
al. 2000; Radoja et al. 1997; de Thé et al. 1990; Tomic-Canic et al. 1992; Vasios et al. 1989) and 
indirect or unknown RA pathways supported the potentiation effect.
RNAseq data was further analyzed with Ingenuity Pathway Analysis (IPA) (Krämer et al. 
2014) software for canonical pathway and upstream regulator prediction. The applied 
significance cutoffs (see Methods) resulted in 1360, 5480, 169, and 3015 differentially 
expressed genes in RHE treated with 1nM atRA, 100nM atRA, 1000nM DX314, and 1000nM 
DX314 with 1nM atRA, respectively. Analysis results were sorted by overall |z-score|, indicating 
the strength and direction of each prediction (positive score = activation, negative score = 
inhibition). As expected, the upstream regulator with largest activation score was atRA 
(tretinoin), which displayed an activation pattern consistent with atRA potentiation (Figure 1d). 
Of the top 20 scoring regulators, only three weakly displayed any predicted activity by DX314 
alone. Canonical pathway analysis (Figure 1e) found the overall most activated (“Integrin 
Signaling”) and inhibited (“RhoGDI Signaling”) pathways both display activation patterns 
suggesting a potentiation of atRA by DX314.
To test the potential of DX314 in certain keratinization disorders, we investigated 
CYP26A1 gene expression in keratinocytes from patients with Darier disease (DD), recessive x-
linked ichthyosis (RXLI), and lamellar ichthyosis (LI). DX314 potentiates the effects of atRA in 
DD RHE (Figure 2a), RXLI full-thickness RHE (Figure 2b), LI RHE (Figure 2c), and RXLI 
monolayer cultures (Figure 2d). Talarozole potentiated atRA in DD RHE and liarozole 
potentiated atRA in RXLI full-thickness RHE.































































Histological analysis shows that atRA induces robust morphological changes in DD RHE 
(Figure 3a) including a dramatic loss of SG (and their filaggrin-containing keratohyalin granules 
(KG)), denucleation and flattening of stratum spinosum (SS) keratinocytes, and an overall 
unhealthy appearance. When treated alone, DX314 and talarozole caused no major 
morphological changes. Co-treatment with talarozole and 1nM atRA shifted the cell 
morphology, most notably with loss of SG and flattening of epidermal keratinocytes, to more 
closely resemble the appearance of high dose atRA. DX314 with atRA also affected morphology 
relative to DX314 alone, but to a lesser extent, with the appearance not significantly different 
than control or only 1nM atRA-treated RHE.
KRT10, a commonly used marker of epidermal differentiation that localizes to the 
suprabasal epidermis, showed reduced expression in atRA-treated RHE (Figure 3b). Treatment 
with DX314 or talarozole alone led to no change in KRT10 localization, but co-treatment with 
near-physiological levels of atRA reduced staining in the lower SS. KRT10 gene expression in 
DD RHE (Figure 3c) was decreased by atRA in a dose-dependent manner and was potentiated 
by DX314 and talarozole. This effect on KRT10 was also observed in healthy RHE (Figure 1c 
and S1).
DX314 induces barrier effects in healthy and diseased RHE
As a measure of barrier integrity, TEER of healthy RHE was assessed. Independent runs 
with RHE from several donors were pooled and normalized to their respective controls (Figure 
4a). High dose atRA significantly decreased TEER. Liarozole and talarozole alone showed no 
effect on TEER, but co-treatment with atRA resulted in significant TEER decrease. Surprisingly, 
in both healthy and LI (Figure 4b) RHE, DX314 alone increased TEER and caused no decrease 































































relative to control with atRA co-treatment. TEWL was similarly affected by atRA, but no 
significant change was seen with DX314 alone.
Morphologically, atRA disrupted LI (Figure 4c) and healthy RHE (Figure S2 and S3) 
structure as described above. DX314 led to no major changes in morphology when dosed alone. 
However, unlike other RAMBAs (Figure S2), DX314 with atRA co-treatment reduced 
disruption in normal morphology (improved SG/KG, more columnar basal keratinocytes, and 
less disorganized upper epidermis). Semi-quantitative analysis of SG surface area (Figure 4d), 
measured in healthy RHE (Figure S3), confirmed a dramatic reduction of the SG by atRA, but 
no significant loss in DX314 treated groups.
The epidermal differentiation complex (EDC) is a cluster of genes on human locus 1q21 
that are essential for epidermal differentiation (Kypriotou et al. 2012). As noted using RNAseq, 
expression of these genes (Figure 4e) is generally consistent with other retinoid-responsive 
genes. However, many cornified envelope (CE) precursor family genes, such as late cornified 
envelope (LCE) and small proline rich (SPRR) proteins, were dramatically downregulated by 
high dose atRA, but not affected by DX314 with atRA, which may play a role in the observed 
barrier effects. In addition, FLG expression was increased 2-fold with the DX314-atRA 
combination, but not with high dose atRA.
Nuclear receptor profiling revealed that DX314 acts as an inverse agonist for RAR-
related orphan receptors (ROR) α and γ (Figure S4), while showing no activity on any other 
nuclear receptors studied.
DX314 reduces epidermal abnormalities in rhino mice
Rhino mice are commonly used as an in vivo model for screening comedolytic and anti-
keratinizing compounds such as retinoids (Ashton et al. 1984; Fort-Lacoste et al. 1999; Griffiths 































































et al. 1993; Seiberg et al. 1997). Overall, DX314 treatment improved skin morphology (Figure 
5). DX314 decreased comedo density (Figure 6a and 6b), increased the mean comedo profile 
(ratio of comedo opening size to internal diameter) (Figure 6c), suggesting comedolysis, and 
induced epidermal thickening (Figure 6d), consistent with previous studies of topical retinoids. 
Again, DX314 treatment did not change TEWL relative to vehicle (Figure 6e). No abnormal 
behavior, adverse skin changes, changes in body weight or DRAIZE scoring (Table S5 and S6) 
were observed throughout the study.
DISCUSSION
Retinoid-based drugs are well-accepted therapeutics for the treatment of many skin 
diseases (Dawson and Dellavalle 2013; Fisher and Voorhees 1996; Vahlquist et al. 2008). 
Despite their efficacy, use often leads to adverse reactions from their wide spectrum of non-
therapeutically relevant endogenous roles, which are exacerbated by metabolic autoinduction and 
tolerance (Digiovanna et al. 2013; Orfanos et al. 1997). A strategy involving RAMBAs showed 
potential in preclinical and clinical studies (Berth-Jones et al. 2000; Bhushan et al. 2001; 
Bovenschen et al. 2007; Giltaire et al. 2009; Kang et al. 1996; Kuijpers et al. 1998; Lucker et al. 
2005; Lucker et al. 1997; Pavez Loriè et al. 2009b; Stoppie et al. 2000; Vahlquist et al. 2014; 
Verfaille et al. 2007a; Van Wauwe et al. 1992), however, first-generation RAMBAs have not 
progressed to approved for clinical use. A highly selective RAMBA, with low risk of adverse 
events, could address the downsides of current treatment options. This study investigates the 
CYP26B1-selective compound, DX314, as a potential next-generation RAMBA.
Potentiation of the effects of a low, physiologically relevant dose of atRA by DX314 in 
healthy and keratinization disorder keratinocytes, but not DX314 in an atRA-free environment, 































































confirms that DX314 acts by inhibiting atRA metabolism. These gene expression patterns were 
reproduced in keratinocyte cultures from individuals with DD and congenital ichthyosis, in 
addition to healthy skin, suggesting that the bioactivity of DX314 can be therapeutically relevant 
in skin disorders.
A broader investigation of gene expression changes using RNAseq also showed a strong 
pattern indicating potentiation of atRA by DX314 on both RARE-promoted, and indirectly 
regulated genes. Pathway analysis found compelling supporting evidence in predicted upstream 
regulator and canonical pathway activation patterns.
Immunostaining confirmed the atRA potentiating effects of DX314 on IVL localization 
in healthy RHE and KRT10 localization in DD RHE.
These experiments showed that DX314 alone had minimal effect on gene expression and 
therefor, minimal potential for off-target adverse effects, despite therapeutically relevant effects 
when paired with endogenous levels of atRA.
Keratinization disorders are associated with intrinsic epidermal barrier disruption and a 
therapy that improves barrier function would be highly desirable. Surprisingly, this study found a 
significant increase in TEER compared to controls in RHE treated with DX314 alone, and unlike 
with liarozole and talarozole, no decrease from control when co-treated with atRA. Although 
higher doses of atRA significantly decreased TEER and DX314 otherwise appeared to potentiate 
the effects of atRA, DX314 with atRA did not impair barrier function below that of the control. 
TEWL in LI RHE, which is expected to increase with retinoid treatment or ablation of CYP26B1 
(Okano et al. 2012), was not increased by DX314 alone or beyond that of 1nM atRA when added 
as co-treatment. DX314 did not decrease TEWL in RHE, however, a lack of correlation between 
in vitro TEWL and barrier function has been previously documented (Chilcott et al. 2002). 































































Despite previous studies in rhino mice showing retinoids inducing substantial increases in TEWL 
(Elias et al. 1981; Gendimenico et al. 1994), our study found a slight, albeit a non-significant, 
decrease in TEWL, which additionally suggests an in vivo barrier-protecting effect.
Morphologically, DX314-treated RHE show dramatically less disruption of the SG and 
KG, and display an overall healthy appearance compared to atRA, liarozole or talarozole-treated 
healthy, DD, and LI RHE. Semi-quantitative analysis of SG surface area also showed a 
significant decrease in atRA-treated RHE, but no significant change in RHE treated with DX314, 
with or without atRA. Nevertheless, DX314-treated RHE tissue sections had a more continuous 
SG/KG layer relative to controls, which may translate to an increase in TEER.
We observed minimal changes in the expression of many cornified envelope precursor 
proteins within the EDC, despite a large decrease in expression by high dose atRA and DX314 
potentiating of the effects of atRA on other retinoid-responsive genes. We speculate that this 
preservation of CE protein expression may contribute to the ameliorative effect of DX314 on 
barrier integrity. In addition, DX314 displays unique inverse agonist activity on RORα and γ. 
Affinity for RORγ may be explained by DX314’s structural similarity to atRA, which has been 
previously shown to bind to, and inhibit, RORγ (Stehlin-Gaon et al. 2003). Conversely, atRA 
was not found to act on RORa, so the DX314 inverse agonism represents another unique 
property. Furthermore, a previously studied topical RORa/γ inverse agonist was found to inhibit 
inflammation in mouse models of atopic dermatitis (Dai et al. 2017), a skin disorder displaying 
pathological barrier disruption. Future investigations should explore the potential link between 
DX314’s RORa/γ activity and its barrier effects, as well as potential contribution to therapeutic 
effects of skin barrier protection.































































Use of rhino mice to study the in vivo effects of dermatologically active compounds such 
as retinoids is well-established, and unlike in vitro, does not require co-treatment with atRA 
since adequate RA is generated in vivo through dietary sources. Reduction of the acne-like cysts 
(comedones), as well as the associated epidermal thickening (hyperplasia), are sensitive to 
retinoid treatment. In this preliminary study, DX314 led to significant improvement overall in 
comedo number (comedones per cm of skin), profile, and induced epidermal thickening. 
Optimization of the DX314 formulation (to eliminate the harsh acetone vehicle), dosing to 
improve bioavailability, and extending the treatment duration are likely to amplify DX314 
efficacy in this model.
We conclude that our results provide strong evidence that DX314, which is known to 
specifically inhibit the RA-metabolizing enzyme CYP26B1, potentiates the effects of 
physiological levels of atRA in keratinocytes from healthy skin and keratinization disorders in 
vitro; may protect from epidermal skin barrier disruption by retinoids; and has a restorative effect 
on changes in vivo rhino mouse skin consistent with previous retinoid treatments. These 
observations merit further investigation as a unique keratinization disorder treatment with the 
ability to simultaneously correct abnormal keratinization while protecting critical skin barrier 
function. Together these findings present an exciting new therapeutic candidate aimed at 
providing improved patient outcomes with minimal adverse effects, in contrast to currently 
available treatments.

































































Healthy and DD primary keratinocytes, provided by Dr. Poumay’s lab (Namur, 
Belgium), were isolated as previously described (Poumay et al. 2004) from skin samples 
provided by Drs. B. Bienfait and J.S. Blairvacq (Clinique St Luc, Namur-Bouge, Belgium). 
Additional healthy keratinocytes were purchased from ThermoFisher (Cascade Biologics, 
Portland, OR). RXLI and LI keratinocytes were provided by Dr. Paller (Northwestern 
University, IL). Details in Table S1.
Monolayer culture and RHE
Monolayer cultures were prepared as previously described (Minner et al. 2010). Upon 
reaching confluence, keratinocytes were treated for 20hr to compounds solubilized in media 
(0.1% DMSO vehicle for all in vitro studies).
RHE were produced as previously described (Poumay et al. 2004; De Vuyst et al. 2014) 
in Epilife media with 1.5mM Ca2+ (Cascade Biologics, Portland, OR), 10ng/mL keratinocyte 
growth factor (Sigma, Saint Louis, MO) and 50µg/mL vitamin C (Sigma, Saint Louis, MO). 
Treatments were started day 7 of growth, refreshed day 9, and halted day 11.
Full-thickness RHE were prepared as previously described (Zheng et al. 2012). Briefly, 
keratinocytes were seeded atop a simulated dermis (collagen matrix containing J2-3T3 
fibroblasts) and allowed to develop into stratified epidermis before receiving a 4-day treatment 
(refreshed day 2).































































RHE histological analysis and immunostaining
RHE were processed as previously described (Frankart et al. 2012; De Vuyst et al. 2014) 
and stained with hematoxylin-eosin (HE) or prepared for immunostaining. Further described in 
Supplementary Methods.
Measures of epidermal barrier function
TEER was measured by a previously described method (Frankart et al. 2012) with a 
ERS-2 voltohmmeter (Millipore, Burlington, MA). TEWL measurement used an AquaFlux 
AF200 evaporimeter (Biox Systems, London, England). For RHE, a sterilized gasket was placed 
between the cell culture insert and TEWL probe to form airtight seal. TEWL was measured over 
60-90s until reaching a steady state. Analysis of SG surface area was performed using 
Fiji/ImageJ (Schindelin et al. 2012). SG surface area, defined by the presence of KG, was 
manually outlined and the area divided by each tissue’s total area.
RNA isolation, RT-qPCR, RNAseq, and bioinformatics 
Details on RT-qPCR, RNA-seq, and bioinformatics (Andrews 2010; Bolger et al. 2014; 
Durinck et al. 2009; Kim et al. 2017; Kim et al. 2016; Kim et al. 2015; Li et al. 2009; Love et al. 
2013; Pertea et al. 2015; RCoreTeam 2018; Zhu et al. 2018) are provided in Supplementary 
Methods. Primer sequences (Giltaire et al. 2009) provided in Table S2.
When applicable, a method described by (Willems et al. 2008) was used to standardize 
the qPCR data to correct for interindividual variability before analysis.
Nuclear receptor profiling
Refer to Supplementary Methods.
































































Eleven RHJ/LeJ rhino mice (2-3 males, 3 females per group) received daily topical 
application of 50µL vehicle (acetone), or 1% DX314, on a 2x2cm area of back skin for 11 days. 
All animal studies were approved by IACUC under NIH guidelines. Details in Supplementary 
Methods.
Statistical analysis
Statistics, apart from separately described RNAseq portion, were performed as described 
in respective figure legends using Prism 6 (Graphpad Software, La Jolla, CA).
Data availability statement
Data available upon request.
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Figure 1: DX314 potentiates atRA gene expression effects in healthy RHE. (a) Relative 
expression of HBEGF, IVL, and CYP26A1 mRNA by RT-qPCR. Symbol underneath indicates 
comparison group (n=3-4 times in duplicate; mean±95% CI; *p≤0.05, **p≤0.01, ***p≤0.001; 
one-way ANOVA with Tukey’s correction; *vs Control, †vs 1nM atRA, ¥vs 10nM atRA, ⨂vs 
DX314-alone, ⊕vs Liarozole-alone). (b) IVL localization in healthy RHE. (c) RNAseq: Relative 
mRNA expression of retinoid-responsive genes in healthy RHE. Non-grey cells differ from 
controls (FDR≤0.05; n=3-5). Adjacent green cell indicates likely RAR-mediated effect based on 
presence of RARE-promotor for respective gene. Predicted activation z-score of (d) upstream 
regulators or (e) canonical pathways determined by IPA software utilizing RNAseq data. Black 
dots indicate statistical insignificance (p≤0.05 and z-score ≥2 or ≤-2). Additional abbreviations: 
Table S4.
Figure 2: DX314 potentiates the effects of atRA on CYP26A1 mRNA expression in 
keratinocytes from individuals with keratinization disorders. Relative CYP26A1 mRNA 
expression by RT-qPCR in; (a) Darier disease RHE, (b) recessive x-linked ichthyosis (RXLI) 
full-thickness RHE, (c) lamellar ichthyosis RHE, and (d) RXLI monolayer keratinocyte cultures. 
RHE were treated for 4 days and monolayer keratinocytes for 20hrs. Statistical significance was 
computed with (a) autoscaled or (b-d) raw dCt values. Symbol below each treatment indicates 
comparison group (n=3 independent replicates with technical duplicates; mean±95% CI; 
*p≤0.05; **p≤0.01; ***p≤0.001; one-way ANOVA with Tukey’s correction; *vs Control, †vs 
1nM atRA, ¥vs 10nM atRA, &vs 100nM atRA, ◆vs 1000nM atRA, ⨂vs DX314-alone, ⊕vs 
Liarozole-alone, ∅vs Talarozole-alone).































































Figure 3: DX314 potentiates the effects of atRA on the expression and localization of 
keratin 10 (KRT10) in Darier disease (DD) RHE. AtRA, but not DX314, induces a loss of 
stratum granulosum. (a) HE staining and (b) immunofluorecent staining of KRT10 (green) 
localization with nuclear stain (blue), in DD RHE treated for 4 days. Scale bars: black = 20µm, 
white =50 µm. (c) Relative KRT10 mRNA expression by qPCR. Symbol below each treatment 
indicates comparison group. (n=3 independent replicates with technical duplicates; mean±95% 
CI; *p≤0.05; **p≤0.01; ***p≤0.001; one-way ANOVA with Tukey’s correction on autoscaled 
values; *vs Control, †vs 1nM atRA, ¥vs 10nM atRA, &vs 100nM atRA, ⨂vs DX314-alone, ∅vs 
Talarozole-alone).
Figure 4: DX314 protects barrier function in RHE. (a) Transepithelial electrical resistance 
(TEER) in healthy RHE. TEER was normalized to control RHEs for each run, then pooled for 
analysis. Graph shows Tukey’s boxplot with outliers. Sample sizes (n) are shown above x-axis. 
(b) LI RHE TEER (top), transepidermal water loss (middle), and the linear correlation between 
the two measures (bottom). (c) HE staining of lamellar ichthyosis (LI) RHE. Scale bar = 50µm. 
(d) Semi-quantitative analysis of relative stratum granulosum (SG) surface area in healthy RHE. 
(e) Relative expression of epidermal differentiation complex (EDC) genes and regulators by 
RNAseq. Colored (non-grey) cells indicate statistical significance from control (FDR≤0.05; n=3-
5). All RHE received a 4-day treatment. (a,b,d) (*p≤0.05; **p≤0.01; ***p≤0.001; one-way 
ANOVA with Dunnett’s correction vs control).































































Figure 5: DX314 reduces rhino mouse skin abnormalities. Representative HE staining of skin 
biopsies from rhino mice topically treated for 11 days with vehicle (acetone) or 1% DX314. 
ImageJ software was used to quantify comedonal number, profile (d/D, ratio of opening to inner 
diameter), and epidermal thickness. Epidermal thickness was measured at multiple points across 
each sample by measuring the sum of epidermal areas (yellow), excluding the corneal layer, and 
dividing by the sum of the length of the basal layers (dotted blue line). Scale bar =200µm.
Figure 6: DX314 treatment reduces comedonal number, induces epidermal thickening, and 
increases comedonal profile, while having no effect on transepidermal water loss (TEWL) 
in treated rhino mice. Semi-quantitative analysis of changes in (a) total (open + closed) and (b) 
open comedonal number, (c) comedonal profile, and (d) epidermal thickness in rhino mice 
topically treated with vehicle (acetone) or 1% DX314 over 11 days. (e) Daily TEWL 
measurements did not reveal any statistically significant differences between treatment groups. 
(n=5-6 mice per treatment; mean±SD; *p≤0.05; **p≤0.01; Student’s t-test vs vehicle control).































































Figure 1: DX314 potentiates atRA gene expression effects in healthy RHE. (a) Relative expression of 
HBEGF, IVL, and CYP26A1 mRNA by RT-qPCR. Symbol underneath indicates comparison group (n=3-4 times 
in duplicate; mean±95% CI; *p≤0.05, **p≤0.01, ***p≤0.001; one-way ANOVA with Tukey’s correction; 
*vs Control, †vs 1nM atRA, ¥vs 10nM atRA, ⨂vs DX314-alone, ⊕vs Liarozole-alone). (b) IVL localization in 
healthy RHE. (c) RNAseq: Relative mRNA expression of retinoid-responsive genes in healthy RHE. Non-grey 
cells differ from controls (FDR≤0.05; n=3-5). Adjacent green cell indicates likely RAR-mediated effect based 
on presence of RARE-promotor for respective gene. Predicted activation z-score of (d) upstream regulators 
or (e) canonical pathways determined by IPA software utilizing RNAseq data. Black dots indicate statistical 
insignificance (p≤0.05 and z-score ≥2 or ≤-2). Additional abbreviations: Table S4. 
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Figure 2: DX314 potentiates the effects of atRA on CYP26A1 mRNA expression in keratinocytes 
from individuals with keratinization disorders. Relative CYP26A1 mRNA expression by RT-qPCR in; (a) 
Darier disease RHE, (b) recessive x-linked ichthyosis (RXLI) full-thickness RHE, (c) lamellar ichthyosis RHE, 
and (d) RXLI monolayer keratinocyte cultures. RHE were treated for 4 days and monolayer keratinocytes for 
20hrs. Statistical significance was computed with (a) autoscaled or (b-d) raw dCt values. Symbol below 
each treatment indicates comparison group (n=3 independent replicates with technical duplicates; 
mean±95% CI; *p≤0.05; **p≤0.01; ***p≤0.001; one-way ANOVA with Tukey’s correction; *vs Control, 
†vs 1nM atRA, ¥vs 10nM atRA, &vs 100nM atRA, ◆vs 1000nM atRA, ⨂vs DX314-alone, ⊕vs Liarozole-alone, 
∅vs Talarozole-alone). 
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Figure 3: DX314 potentiates the effects of atRA on the expression and localization of keratin 10 
(KRT10) in Darier disease (DD) RHE. AtRA, but not DX314, induces a loss of stratum granulosum. 
(a) HE staining and (b) immunofluorecent staining of KRT10 (green) localization with nuclear stain (blue), 
in DD RHE treated for 4 days. Scale bars: black = 20µm, white =50 µm. (c) Relative KRT10 mRNA 
expression by qPCR. Symbol below each treatment indicates comparison group. (n=3 independent replicates 
with technical duplicates; mean±95% CI; *p≤0.05; **p≤0.01; ***p≤0.001; one-way ANOVA with Tukey’s 
correction on autoscaled values; *vs Control, †vs 1nM atRA, ¥vs 10nM atRA, &vs 100nM atRA, ⨂vs DX314-
alone, ∅vs Talarozole-alone). 
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Figure 4: DX314 protects barrier function in RHE. (a) Transepithelial electrical resistance (TEER) in 
healthy RHE. TEER was normalized to control RHEs for each run, then pooled for analysis. Graph shows 
Tukey’s boxplot with outliers. Sample sizes (n) are shown above x-axis. (b) LI RHE TEER (top), 
transepidermal water loss (middle), and the linear correlation between the two measures (bottom). (c) HE 
staining of lamellar ichthyosis (LI) RHE. Scale bar = 50µm. (d) Semi-quantitative analysis of relative 
stratum granulosum (SG) surface area in healthy RHE. (e) Relative expression of epidermal differentiation 
complex (EDC) genes and regulators by RNAseq. Colored (non-grey) cells indicate statistical significance 
from control (FDR≤0.05; n=3-5). All RHE received a 4-day treatment. (a,b,d) (*p≤0.05; **p≤0.01; 
***p≤0.001; one-way ANOVA with Dunnett’s correction vs control). 
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Figure 5: DX314 reduces rhino mouse skin abnormalities. Representative HE staining of skin biopsies 
from rhino mice topically treated for 11 days with vehicle (acetone) or 1% DX314. ImageJ software was 
used to quantify comedonal number, profile (d/D, ratio of opening to inner diameter), and epidermal 
thickness. Epidermal thickness was measured at multiple points across each sample by measuring the sum 
of epidermal areas (yellow), excluding the corneal layer, and dividing by the sum of the length of the basal 
layers (dotted blue line). Scale bar =200µm. 
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Figure 6: DX314 treatment reduces comedonal number, induces epidermal thickening, and 
increases comedonal profile, while having no effect on transepidermal water loss (TEWL) in 
treated rhino mice. Semi-quantitative analysis of changes in (a) total (open + closed) and (b) open 
comedonal number, (c) comedonal profile, and (d) epidermal thickness in rhino mice topically treated with 
vehicle (acetone) or 1% DX314 over 11 days. (e) Daily TEWL measurements did not reveal any statistically 
significant differences between treatment groups. (n=5-6 mice per treatment; mean±SD; *p≤0.05; 
**p≤0.01; Student’s t-test vs vehicle control). 
113x110mm (600 x 600 DPI) 

































































Slides were sequentially exposed to the following: PBS rinse, 2x 3min 0.1M glycine in dH2O, 
PBS rinse, then 1hr in PBS/BSA/Triton (PBS with 0.2% BSA and 0.02% Triton X-100). A 
hydrophobic marker was used to encircle the tissue and 50µL of primary antibody (diluted in 
PBS/BSA/Triton) was applied. The slides were placed in a humidity chamber and incubated for 
1hr at room temperature. The slides were then rinsed three times in PBS/BSA/Triton before 1hr 
humidified incubation with 50µL of the respective secondary antibody. The slides were again 
rinsed three times in PBS/BSA/Triton before a 15min incubation with 50µL of Hoechst nuclear 
stain (diluted in PBS/BSA/Triton) followed by 3x 5min PBS rinses. Coverslips were mounted 
with Mowiol 40-88 and the slides were stored at 4°C until imaged on an Olympus DX63 
microscope with Olympus XM10 camera. Antibodies and dilutions can be found below (Table 
S3).
RNA isolation and quantitative PCR
Following treatment, RHEs intended for RNA extraction were flash frozen at -80°C until use. 
RNA was isolated using the NucleoSpin RNA (Macherey-Nagel, Bethlehem, PA) kit, as 
recommended by the manufacturer. Variations from the standard protocol include 
homogenization with 600µL (rather than 350µL) of RA1 lysis buffer, addition of 6µL of β-
mercaptoethanol to RA1 to aid tissue lysis, and addition 600µL of 70% ethanol (rather than 
350µL) during nucleic acid precipitation. RNA obtained from monolayer and full-thickness RHE 
cultures were isolated using TRIzol (Life Technologies, Burlington, Canada) phenol-chloroform 
extraction as described by the manufacturer. Variations from the standard protocol include 
chilling the sample following the addition of isopropanol to encourage nucleic acid precipitation, 































































and the addition of a second chilled 75% ethanol wash prior to drying the pellet, which greatly 
improved consistency in RNA purity.
Isolated RNA purity and concentration were measured by NanoDrop 2000c (Thermo 
Scientific, Rockford, IL) and integrity was confirmed by gel electrophoresis. 100-200ng of 
template RNA was reverse-transcribed to cDNA with the Superscript III reverse transcriptase kit 
(Invitrogen, Aalst, Belgium). The cDNA was then diluted 1:10 with water. 2µL of cDNA was 
added to a 10µL real-time qPCR reaction, which used Takyon No ROX SYBR 2X MasterMix 
(Eurogentec, Seraing, Belgium) on a Roche Lightcycler 96 (activation: 3min - 95°C; 40 cycles: 
10sec - 95°C, 20sec - 60°C, 30sec - 72°C). 500nM of each primer pair (Table S2), optimized for 
an annealing temperature of 60°C, was used for each reaction. RPL13a and 36B4 (RPLP0) were 
used as reference genes.
RNA sequencing and bioinformatics
RNA samples were sent to the University of Colorado’s Genomics and Sequencing Core 
Facility (Denver, CO) for library preparation and sequencing. Purity and concentration were 
measured with an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). 200-500ng of 
RNA was used to prepare the Illumina HiSeq libraries according to manufacturer’s instructions 
for the TruSeq Stranded RNA kit (Illumina, San Diego, CA). Sequencing was done as 2x151bp 
paired end reads on the Illumina HiSeq4000. The bioinformatics pipeline used was an adaptation 
of several described methods (Kim et al. 2016; Love et al. 2013): FastQC (Andrews 2010) 
(v0.11.3) → Trimmomatic (Bolger et al. 2014) (v0.38) → FastQC → Hisat2 (Kim et al. 2015) 
(v2.1.0) → SamTools (Li et al. 2009) (v1.8) → Stringtie (Pertea et al. 2015) (v1.3.4d). Reads 
were mapped to the H. sapien GRCh38 genome_tran index provided by HiSat2 developers (Kim 
et al. 2017). Differential expression analysis was performed in R (RCoreTeam 2018) (v3.5.2) 































































using DESeq2 (Love et al. 2014) (v1.22.2). False-discovery rate (FDR) was determined with the 
Benjamini-Hochberg correction, logarithmic-fold change shrinkage to correction was performed 
using the apeglm (Zhu et al. 2018) (v1.4.2) algorithm, HGNC names were attached using 
BiomaRt (Durinck et al. 2009) (v2.38.0). Treatment groups: Control (n=5), 1nM atRA (n=4), 
100nM atRA (n=4), 1000nM DX314 (n=3), and 1000nM DX314 + 1nM atRA (n=4).
Fold-change (FC) and FDR values mapped to Ensembl IDs were imported into Ingenuity 
Pathway Analysis (IPA) (Qiagen, Germantown, MD) software for analysis. Analysis was limited 
to genes with FDR ≤ 0.05, and FC ≥ 1.5 or ≤ -1.5. IPA uses Fisher’s exact test (p≤0.05) to 
predict the activation or inhibition of canonical pathways and upstream regulators. A z-score of ≥ 
2.0 is considered activated, a z≤ -2.0 is considered inhibited.
Nuclear receptor profiling
Nuclear receptor activity profiling was performed by luciferase gene reporter assay using 
the Steady-Glo luciferase assay system (Promega, E2550) and 16 recombinant HeLa cell lines in 
which the respective human nuclear receptors were overexpressed. Compounds were solubilized 
at 10mM in DMSO and all assays were performed at a final concentration of 0.1% DMSO. 
Dose-response curves were generated with 8 compound concentrations (n=2) in 4-fold serial 
dilutions from a maximum test dose of 10µM. Cells in growth media (DMEM with 1g/L glucose 
(Invitrogen, 31885-023), 2mM L-glutamine (Invitrogen, 25030-024), 1x MEM non-essential 
amino acids (Invitrogen, 11140-035), 0.1% antibiotic-antimycotic (Invitrogen, 15240-062), 
0.5mg/mL G418 (Invitrogen, 10131-027), 0.5µg/mL puromycin (Sigma, P8833), 10% FBS 
(Biowest, S800)) were seeded in 96-well plates at 2e4 cells/well and incubated at 37°C with 5% 
CO2 for 4hrs. Compounds in test media (growth media with 0.1% Pluronic F-127 (Interchim, FP-
379951)) were then added to each well and the plates were returned to the incubator for 18-































































24hrs. 50µL/well of Steady-Glo was added to each well and plates were shaken for 5min at room 
temperature before measuring luciferase activity (RLU) using a BMG Clariostar plate reader.
Data was normalized to negative (Min) and positive (Max) controls: . 4-
(𝑥 ― 𝑀𝑖𝑛) ∗ 100
(𝑀𝑎𝑥 ― 𝑀𝑖𝑛)
parameter logistic model fitting was performed using XLfit software (IDBS). Where n is the hill 







Rhino mice (2-3 males, 3 females per group), aged 5-7 weeks were acquired from 
Jackson Laboratory (Sacramento, CA) and acclimated to standard housing and provisions for one 
week prior to start. All animal studies were approved by Institutional Animal Care and Use 
Committee under NIH guidelines. Mice received daily topical application of 50µL vehicle 
(acetone), or freshly made 1% DX314, on a 2x2cm area of back skin for 11 days. Daily clinical 
observations, body weights, TEWL, and DRAIZE scoring were recorded (Table S5 and S6). 
Mice underwent necropsy on day 12 and skin tissue was collected and processed.
Quantitative analysis of the tissue was performed using Fiji/ImageJ software following a 
previously described standardized method (Bouclier et al. 1991). Each sample was analyzed at 
least two different section depths and totaling 6.2-12.8mm of skin per subject. Open comedone 
profile was quantified as the ratio of the opening size (d) and the internal diameter (D). 
Epidermal thickness was measured (17+ unique points per subject) by measuring the epidermal 
area, excluding the SC, and dividing by the length of the underlying basal layer (Figure 5).































































Keratinocytes Source Pathology Age/Sex Figure(s)
NAK209 48/F 1a-b, 4a
NAK219 37/M 1a, 4a
NAK214
Poumay/Bienfait
32/F 1a, 4a, S1, S2
HEKa Gibco, C0055C
Healthy
40/F 1c-e, 4d-e, S3







Lamellar ichthyosis 9/M 2c, 4b-c






































































































































Target Species Dilution Source
IVL Mouse 1:200 Invitrogen, I9018
KRT10 Mouse 1:100 DAKO, M7002
2°, HRP-conjugated 
(anti-mouse) Horse 1:100 Vectastain, PK-4002
2°, Alexa Fluor 
488-conjugated 
(anti-mouse)
Goat 1:1000 Life Technologies, A11001
Hoechst 33258, 
nuclear stain - 1:100 Life Technologies, H3569
































































ANOVA analysis of variance
AQP aquaporin
ARNT aryl hydrocarbon receptor nuclear translocator
ARP actin-related protein
atRA all-trans retinoic acid
BHLH basic helix-loop-helix




CRABP cellular retinoic acid binding protein
CRBP cellular retinol binding protein








EDC epidermal differentiation complex
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EHF ETS homologous factor
ELF E74 like ETS transcription factor
ERBB Erb-B2 Receptor Tyrosine Kinase
Erk extracellular signal-regulated kinases
FBS fetal bovine serum
FDR false discovery rate
FGF fibroblast growth factor
FLG filaggrin
GATA GATA binding protein
GRHL grainyhead like transcription factor
GTF gene transfer format
HBEGF heparin-binding EGF-like growth factor
HE hematoxylin and eosin
HGNC HUGO gene nomenclature committee
HIC HIC ZBTB transcriptional repressor







IPA ingenuity pathway analysis
IVL involucrin
JAK/STAT janus kinases/signal transducer and activator of transcription































































JAM junctional adhesion molecules
KG keratohyalin granules
KGF keratinocyte growth factor
KLF kruppel-like factor
KLK kallikrein related peptidase
KRT keratin
LAMB laminin subunit beta




LXR liver X receptor
MAPK mitogen-activated protein kinases
MEIS Meis homeobox
ML Monolayer
NFE nuclear factor, erythroid
NR nuclear receptor




PBS phosphate buffered saline






RAMBA retinoic acid metabolism blocking agents
RAR retinoic acid receptor
RARE retinoic acid response element
RARRES retinoic acid receptor responder
RB1 retinoblastoma-associated protein
RBP retinol binding protein
RE retinyl esters
RHE reconstructed human epidermis
RHOGDI RHO protein GDP dissociation inhibitor
RNA ribonucleic acid
ROL retinol/vitamin A
ROR RAR-related orphan receptor
RPTN repetin
RT qPCR real-time quantitative polymerase chain reaction
RXLI recessive x-linked ichthyosis
RXR retinoid X receptor
S100 S100 calcium binding protein




































































SMARC SWI/SNF-related matrix-associated actin-dependent regulator of chromatin
SPINK serine protease inhibitor kazal-type
SPR small proline-rich protein
SS stratum spinosum
SSWL subsurface water loss
STRA stimulated by retinoic acid
TCHH/THH trichohyalin
TEER transepithelial electrical resistance
TEWL trans-epidermal water loss





TNF tumor necrosis factor
TP53 tumor protein p53
TR thyroid receptor
TREM triggering receptor expressed on myeloid cells
TTR transthyretine
UV ultraviolet
VDR vitamin D receptor
WASP Wiskott–Aldrich Syndrome protein
Wnt wingless/integrated
ZO zona occludens































































Group Animal Number Clinical Observation (Days Observed)
101* NSO (Day 0-5), slight dry skin on upper back (Day 6), dry skin on upper back (Day 7-8), slight dry skin on upper back (Day 9-11) NSO Day 12)
102* NSO (Day 0-8), very slight dry skin on upper back (Day 9), NSO (Day 10-12)
103* NSO (Day 0-5), slight dry skin on upper back (Day6-7), NSO (Day 8), two small bite marks at base of tail (Day 9-11), NSO (Day 12)
152˄ NSO (Day 0-6), Slight dry skin on upper back (Day 7-8), NSO (Day 9), Slight dry skin on upper back (Day 10-11), NSO (Day 12)
Vehicle
153˄ NSO (Day 0-7), Slight dry skin on upper back (Day 8), NSO (Day 9-12)
401* NSO (Day 0-5), Slight dry skin on upper back (Day 6-8), brown/tan patch across mid back (Day 9-12)
402* NSO (Day 0-6), Dry skin on upper back (Day 7), Slight dry skin on upper back (Day 8), Brown/tan patch across mid back (Day 9-12)
403* NSO (Day 0-6), Dry skin on upper back (Day 7), Slight dry skin on upper back (Day 8), Darker brown/tan patch across mid back (Day 9-12)
451˄ NSO (Day 0-6), slight dry skin on upper back (Day 7-8), NSO (Day 9-11), slight tan patch on mid back (Day 12)
452˄ NSO (Day 0-6), Slight dry skin on upper back (Day 7-8), NSO (Day 9-12)
1% 
DX314
453˄ NSO (Day 0-6), Slight dry skin on upper back (Day 7-8), NSO (Day 9-11), OD: corneal edema, swollen and opaque; tan patch on back (Day 12)
































































Day 0 Day 7 Day 12
DRAIZE Scoring 
(Erythema : Edema)Group Animal
g % g % g % Day 0 Day 7 Day 12
101* 24.5 100.0 20.8 84.9 21.9 89.4 0 : 0 0 : 0 0 : 0
102* 24.4 100.0 25.9 106.1 25.2 103.3 0 : 0 0 : 0 0 : 0
103* 18.5 100.0 19.1 103.2 19.8 107.0 0 : 0 0 : 0 0 : 0
152˄ 19.3 100.0 19.6 101.6 19.7 102.1 0 : 0 0 : 0 0 : 0
Vehicle
153˄ 21.9 100.0 21.8 99.5 23.2 105.9 0 : 0 0 : 0 0 : 0
401* 23.4 100.0 23.1 98.7 23.8 101.7 0 : 0 0 : 0 0 : 0
404* 22.6 100.0 23.2 102.7 23.4 103.5 0 : 0 0 : 0 0 : 0
403* 21.9 100.0 22.8 104.1 23.2 105.9 0 : 0 0 : 0 0 : 0
451˄ 19.1 100.0 19.7 103.1 20.5 107.3 0 : 0 0 : 0 0 : 0
452˄ 21.4 100.0 22.4 104.7 22.3 104.2 0 : 0 0 : 0 0 : 0
1% DX314
453˄ 20.6 100.0 20.7 100.5 21.4 103.9 0 : 0 0 : 0 0 : 0































































Figure S1: DX314 potentiates the effects of atRA on KRT10 localization in healthy RHE. 
Immunofluorescent staining of KRT10 (green) localization with nuclear stain (blue) in healthy RHE treated 
for 4 days. Scale bar =50µm. 
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Figure S2: AtRA causes abnormal morphological effects in healthy RHE, which are potentiated by 
liarozole and talarozole, but not DX314. HE staining of healthy RHE treated for 4 days by atRA or 
RAMBAs with, and without, atRA. Scale bar =20µm. (SC, stratum corneum; SG, stratum granulosum; SS, 
stratum spinosum; SB, stratum basale). 
110x92mm (300 x 300 DPI) 































































Figure S3: Tissues used in semi-quantitative analysis of relative stratum granulosum (SG) 
surface area. Healthy RHE were treated for 4 days before processing, HE staining, and imaging. Shown are 
cropped images of the samples used to determine SG surface area as a percent of total tissue surface area 
(Figure 4d). Scale bar =50µm. 
169x100mm (300 x 300 DPI) 































































Figure S4: DX314 acts as an inverse agonist on RORα and RORγ, displays no activity on other 
nuclear receptors. (a) Table of EC50 values for DX314 and respective reference ligand. Non-linear 
regression of normalized (b) RORα and (c) RORγ luciferase reporter assay activity. IA = Inactive. 
233x103mm (300 x 300 DPI) 
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